HC Wainwright Has Positive Outlook for ABEO FY2024 Earnings

Abeona Therapeutics Inc (NASDAQ:ABEO) – HC Wainwright upped their FY2024 EPS estimates for Abeona Therapeutics in a report released on Monday, November 25th. HC Wainwright analyst R. Selvaraju now forecasts that the biopharmaceutical company will earn ($1.16) per share for the year, up from their prior forecast of ($1.26). HC Wainwright currently has a “Buy” rating and a $15.00 target price on the stock. The consensus estimate for Abeona Therapeutics’ current full-year earnings is ($1.21) per share. HC Wainwright also issued estimates for Abeona Therapeutics’ Q4 2024 earnings at ($0.34) EPS, Q1 2025 earnings at ($0.34) EPS, Q2 2025 earnings at ($0.36) EPS and FY2025 earnings at ($1.17) EPS.

A number of other analysts also recently issued reports on ABEO. Cantor Fitzgerald reiterated an “overweight” rating and issued a $18.00 price target on shares of Abeona Therapeutics in a report on Tuesday, October 29th. StockNews.com upgraded shares of Abeona Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th.

Abeona Therapeutics Stock Performance

Shares of NASDAQ ABEO opened at $6.41 on Wednesday. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.12 and a current ratio of 6.12. The company has a market cap of $278.64 million, a P/E ratio of -2.39 and a beta of 1.52. The firm’s fifty day moving average is $6.22 and its two-hundred day moving average is $5.32. Abeona Therapeutics has a 52-week low of $3.05 and a 52-week high of $9.01.

Institutional Trading of Abeona Therapeutics

Large investors have recently made changes to their positions in the business. Simplify Asset Management Inc. bought a new stake in shares of Abeona Therapeutics in the 2nd quarter worth about $1,732,000. abrdn plc increased its holdings in shares of Abeona Therapeutics by 158.8% in the 3rd quarter. abrdn plc now owns 326,995 shares of the biopharmaceutical company’s stock worth $2,067,000 after buying an additional 200,647 shares during the last quarter. Renaissance Technologies LLC boosted its stake in shares of Abeona Therapeutics by 581.6% during the 2nd quarter. Renaissance Technologies LLC now owns 503,293 shares of the biopharmaceutical company’s stock worth $2,134,000 after purchasing an additional 429,456 shares during the period. Acadian Asset Management LLC purchased a new position in shares of Abeona Therapeutics during the 1st quarter worth about $91,000. Finally, Rosalind Advisors Inc. boosted its stake in shares of Abeona Therapeutics by 4.7% during the 3rd quarter. Rosalind Advisors Inc. now owns 1,832,000 shares of the biopharmaceutical company’s stock worth $11,578,000 after purchasing an additional 82,000 shares during the period. 80.56% of the stock is currently owned by institutional investors.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.